Collectively, these findings highlight the link between macrophage polarization and clinical outcomes in prostate cancer, suggesting that combining IL-8/CXCR2 inhibition with existing immunotherapies may offer synergistic benefits for patients. The gene discussed is CXCL8; the disease is prostate carcinoma.